{"id":"W2592994249","doi":"10.1158/1538-7445.sabcs16-p4-22-06","title":"Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Palbociclib; Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Hazard ratio; Breast cancer; Progression-free survival; Cancer; Oncology; Chemotherapy; Placebo; Gynecology; Tamoxifen; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006308164,0.0005746144,0.00105818,0.0005266038,0.0004591704,0.0001594007,0.000628139,0.0001746577,0.0009257027],"category_scores_gemma":[0.00007978477,0.0004236504,0.00009265084,0.000569396,0.0008335046,0.0005537405,0.0001560135,0.001070183,0.00002632232],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007236811,"about_ca_system_score_gemma":0.002154371,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01390155,"about_ca_topic_score_gemma":0.01343401,"domain_scores_codex":[0.9946932,0.0001793361,0.0006360347,0.001192535,0.001287778,0.00201118],"domain_scores_gemma":[0.9969857,0.0001660553,0.0002993352,0.001473162,0.0004717186,0.0006040607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.08708958,0.0009949948,0.1418656,0.000719488,0.0003507771,0.003455239,0.005033411,0.0008152225,0.1742586,0.00004814939,0.00009595171,0.585273],"study_design_scores_gemma":[0.022172,0.001354664,0.9486552,0.005385181,0.00002446742,0.0000812374,0.001881893,0.00004504195,0.0126786,0.0001947522,0.007000048,0.0005268612],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840457,0.005567292,0.00000270506,0.006729344,0.0001395991,0.002180611,0.0002650313,0.00007445018,0.0009952715],"genre_scores_gemma":[0.9868677,0.006844601,0.0002350339,0.0001210393,0.0003517101,0.004179331,0.00002093454,0.0001463043,0.001233349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8067896,"threshold_uncertainty_score":0.9999876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05030317000219856,"score_gpt":0.4175466863526979,"score_spread":0.3672435163504993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}